Melody Transcatheter Pulmonary Valve (TPV) Post-Market Surveillance Study

NCT ID: NCT00688571

Last Updated: 2015-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This non-randomized, prospective, interventional observational multi-center study is designed to assess the long-term clinical performance of the Medtronic Melody™ Transcatheter Pulmonary Valve (TPV) in the post market environment over a period of five years after transcatheter implantation in patients with dysfunctional RVOT conduits. In addition, the quality of life of implanted subjects will be assessed over five years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Valve Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Melody TPV Implant

Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.

Group Type EXPERIMENTAL

Melody Transcatheter Pulmonary Valve

Intervention Type DEVICE

Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Melody Transcatheter Pulmonary Valve

Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 5 years of age
* Weight greater than or equal to 30 kilograms
* Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted
* Any of the following by transthoracic echocardiography

For patients in NYHA Classification II, III, or IV:

* Moderate (3+) or severe (4+) pulmonary regurgitation, or
* Mean RVOT gradient greater than or equal to 35 mmHg.

For patients in NYHA Classification I:

* Severe (4+) pulmonary regurgitation with RV dilatation or dysfunction, or
* Mean RVOT gradient greater than or equal to 40 mmHg.

Exclusion Criteria

* Active endocarditis
* A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year
* Patient or - for patients who cannot legally give consent themselves- the guardian unwilling or unable to provide written informed consent or comply with follow-up requirements
* Obstruction of the central veins (including the superior and inferior vena cava, bilateral iliac veins) such that the delivery system cannot be advanced to the heart via transvenous approach from either femoral vein or internal jugular vein
* Known intravenous drug abuse
Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role collaborator

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Hess, Prof.

Role: PRINCIPAL_INVESTIGATOR

Deutsches Herzzentrum München

Felix Berger, Prof.

Role: PRINCIPAL_INVESTIGATOR

German Heart Institute

Lars Soendergaard, Dr.

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Maria Giulia Gagliardi, Dr.

Role: PRINCIPAL_INVESTIGATOR

Ospedale Bambino Gesu Rome

Jose Suarez de Lezo, Dr.

Role: PRINCIPAL_INVESTIGATOR

Hospital Reina Sofia Cordoba

Lee Benson, Dr.

Role: PRINCIPAL_INVESTIGATOR

The Hospital for Sick Children

Maarten Witsenburg, Dr.

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status

Rigshospitalet Copenhagen

Copenhagen, , Denmark

Site Status

Deutsches Herzzentrum Berlin

Berlin, , Germany

Site Status

Deutsches Herzzentrum München

München, , Germany

Site Status

Hospital Bambino Gesu Roma

Rome, , Italy

Site Status

Erasmus Medical Center

Rotterdam, , Netherlands

Site Status

Hospital Reina Sofia

Córdoba, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Denmark Germany Italy Netherlands Spain

References

Explore related publications, articles, or registry entries linked to this study.

Armstrong AK, Berger F, Jones TK, Moore JW, Benson LN, Cheatham JP, Turner DR, Rhodes JF, Vincent JA, Zellers T, Lung TH, Eicken A, McElhinney DB. Association between patient age at implant and outcomes after transcatheter pulmonary valve replacement in the multicenter Melody valve trials. Catheter Cardiovasc Interv. 2019 Oct 1;94(4):607-617. doi: 10.1002/ccd.28454. Epub 2019 Aug 16.

Reference Type DERIVED
PMID: 31419019 (View on PubMed)

McElhinney DB, Benson LN, Eicken A, Kreutzer J, Padera RF, Zahn EM. Infective endocarditis after transcatheter pulmonary valve replacement using the Melody valve: combined results of 3 prospective North American and European studies. Circ Cardiovasc Interv. 2013 Jun;6(3):292-300. doi: 10.1161/CIRCINTERVENTIONS.112.000087. Epub 2013 Jun 4.

Reference Type DERIVED
PMID: 23735475 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BRC-CS-PMSS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Medtronic CoreValve REDO Study
NCT01051310 COMPLETED NA
The Nordic Aortic Valve Intervention Trial
NCT01057173 ACTIVE_NOT_RECRUITING NA